Clinical trial

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

NCT01507428

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-02-22

PhasePHASE2

Study timeline

Study start (actual)2012-02-22Date precision: day

Registry last updated2026-04-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Stage III Lung Non-Small Cell Cancer AJCC v7unresolved

Stage IIIA Lung Non-Small Cell Cancer AJCC v7unresolved

Stage IIIB Lung Non-Small Cell Cancer AJCC v7unresolved

Interventions

18F-FluoromisonidazoleDRUG

CarboplatinDRUG · verified · RxNorm: carboplatin

Computed TomographyPROCEDURE

Computed TomographyPROCEDURE

External Beam Radiation TherapyRADIATION

Fludeoxyglucose F-18DRUG

Image-Guided Adaptive Radiation TherapyRADIATION

Laboratory Biomarker AnalysisOTHER

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Positron Emission TomographyPROCEDURE

Positron Emission TomographyPROCEDURE

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

NRG Oncologycollaborator

Mapped research locations

ClevelandOhio, United States3 PhiladelphiaPennsylvania, United States2 New YorkNew York, United States1 ChicagoIllinois, United States1 St LouisMissouri, United States1 MontrealQuebec, Canada1 IndianapolisIndiana, United States1 Oklahoma CityOklahoma, United States1 Ann ArborMichigan, United States1 CharlestonSouth Carolina, United States1 MilwaukeeWisconsin, United States1 LouisvilleKentucky, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01507428 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.